New vaccine against flu, other
diseases, developed at Hebrew University
A group of researchers at the Hebrew University of Jerusalem has developed an
effective new method for administering vaccines against influenza and other
diseases through nasal drops or sprays.
The Yissum Research Development Company of the Hebrew University has applied
for a patent for the new method and is in contact with international
pharmaceutical companies with a view towards commercialization.
The research group includes Eli Kedar, the Bernard L. and Mary T. Sachs
Professor of Cancer Studies; Yechezkel Barenholz, the Dr. Daniel G. Miller
Professor of Cancer Research; and doctoral candidate Aviva Joseph. For her
research work on this project, Joseph has been selected as one of this year's
winners of a Kaye Innovation Award, which was presented on May 27 during the
66th meeting of the Hebrew University Board of Governors. This is the tenth
anniversary year of the Kaye Awards.
The outbreak of SARS (severe acute respiratory syndrome) has given even
greater importance to the development of immunizations caused by viruses or
bacteria. Added to this is the threat of biological terror attacks and the
constant dread of a world-wide outbreak of new strains of influenza.
Existing vaccines are not sufficiently effective among the infirm elderly
whose immune system is deficient due to age; those whose immune system has been
damaged due, for example, to exposure to AIDS; or those who are receiving
treatments that repress the immune system, such as cancer patients undergoing
chemotherapy.
Despite the fact that most disease-causing microorganisms (or pathogens)
enter the body either through the respiratory or digestive systems, the great
majority of vaccines today are given through injection into muscular tissue. The
injections administered to the muscle do not provide, in many cases, sufficient
protection against the infectious agent at the point of its entry into the body.
The advantage of the new method developed by the Hebrew University
researchers is that the drops or spray administered through the nose are capable
of stopping infections at the point of entry. Also, it overcomes the fear of
many people to injections and can be self-administered. This type of treatment
can be given easily to large populations within a relatively short period of
time, thereby halting the threat of widespread dispersal. This also gives a
particular advantage in trying to reach remote areas.
The new method is based on new formulations of tiny fatty spheres
(liposomes), which are positively charged and are capable of transporting
proteins from infectious agents. When the vaccine containing the liposomes is
administered, the immune system is aroused, providing a rapid and simple means
for providing protection. In an earlier stage of the research, this method was
applied experimentally in injection form, however more recently a formula for
drops has been developed (it can also be adapted for nasal sprays). The drops
are to be taken two times, one week apart, in order to achieve immunity. The
researchers are aiming at achieving a one-dose immunization.
In laboratory tests on mice, the new formula was found to be significantly
more effective in protecting against influenza than existing, commercial
vaccines. Preliminary studies with other human pathogens yielded promising
results as well. Additional trials are being carried out in the laboratory
before human clinical trials will be attempted.
The Kaye Innovation Awards at the Hebrew University were established in 1994
by Isaac Kaye of England, a prominent industrialist in the pharmaceutical
industry, to encourage faculty, staff and students of the university to develop
innovative methods and inventions with good commercial potential, which have
benefited or will benefit the university and society.
DISCLAIMER: All
information, data, and material contained, presented, or provided here is for
general information purposes only and is not to be construed as reflecting the
knowledge or opinions of the publisher, and is not to be construed or intended
as providing medical or legal advice. The decision whether or not to vaccinate
is an important and complex issue and should be made by you, and you alone, in
consultation with your health care provider.
"A foolish faith in authority is the worst enemy of truth."
-- Albert Einstein, letter to a friend, 1901
"I know of no safe depository of the ultimate powers of the society but the people themselves, and if we think them not enlightened enough to exercise control with a wholesome discretion, the remedy is not to take it from them, but to inform their discretion by education."
-- Thomas Jefferson, letter to William C. Jarvis, September 28, 1820
"What's the point of vaccination if it doesn't protect you from the unvaccinated?"
-- Sandy Gottstein
"Who gets to decide what the greater good is and how many will be sacrificed to it?"